Andrew D. Spencer
Expertise in
4
conditions

Dr. Andrew D. Spencer

General Surgery
1959 Ne Pacific St Box #356410, 
Seattle, WA 
Expertise in
4
conditions
1959 Ne Pacific St Box #356410, 
Seattle, WA 

Overview

Andrew Spencer is a General Surgeon in Seattle, Washington. Dr. Spencer is highly rated in 4 conditions, according to our data. His top areas of expertise are Febrile Neutropenia, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 277 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

General Surgery

Licenses

Surgery in WA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1959 Ne Pacific St Box #356410, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 4 Less Clinical Trials

277 Total Publications

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 11, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Flavio Rocha
General Surgery
Expertise in
21
conditions
Dr. Flavio Rocha
General Surgery

Virginia Mason Medical Center

1100 9th Ave, 
Seattle, WA 
 (2.9 miles away)
206-341-1904
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Flavio Rocha is a General Surgeon in Seattle, Washington. Dr. Rocha is highly rated in 21 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
10
conditions
Dr. Brant K. Oelschlager
General Surgery
Expertise in
10
conditions
Dr. Brant K. Oelschlager
General Surgery

The Association Of University Physicians

1701 Columbia Rd, 
Seattle, WA 
 (0.1 miles away)
206-598-3100
Languages Spoken:
English, Filipino, French, Khmer, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Brant Oelschlager is a General Surgeon in Seattle, Washington. Dr. Oelschlager is highly rated in 10 conditions, according to our data. His top areas of expertise are Hiatal Hernia, Diaphragmatic Hernia, Hernia, Endoscopy, and Gastrectomy. Dr. Oelschlager is currently accepting new patients.

David R. Flum
Expertise in
8
conditions
Dr. David R. Flum
General Surgery
Expertise in
8
conditions
Dr. David R. Flum
General Surgery

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (0.2 miles away)
206-598-4333
Languages Spoken:
English, Castilian, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Flum is a General Surgeon in Seattle, Washington. Dr. Flum is highly rated in 8 conditions, according to our data. His top areas of expertise are Appendicitis, Diverticular Disease, Obesity, Appendectomy, and Gastric Bypass. Dr. Flum is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew D. Spencer

How do I make an appointment with Dr. Andrew D. Spencer?

You can book an appointment with Dr. Andrew D. Spencer by calling their office at 206-543-3654. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew D. Spencer a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew D. Spencer is classified as an Distinguished expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew D. Spencer specialize in?

While Dr. Andrew D. Spencer is a General Surgery, they have specific expertise in Febrile Neutropenia, Bone Marrow Transplant, and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Andrew D. Spencer participate in research or clinical trials?

Yes. Dr. Andrew D. Spencer has published 277 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Dr. Andrew D. Spencer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spencer's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile